Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-05-02 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Completes Acquisition of QSAM 3 pages 156.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement by Telix Pharmaceuticals Limited about the completion of an acquisition of QSAM Biosciences and its bone cancer targeting platform. It details transaction terms, including share issuance and contingent value rights, and provides background on the acquired technology and company. The content focuses on a corporate transaction (acquisition) and financing terms related to the acquisition, including share issuance and contingent payments. There are no financial statements, quarterly or annual results, or audit information. The document is not a report but an announcement of a corporate transaction and financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2024-05-02 English
Pending Release of Shares from Voluntary Escrow 2 pages 147.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX release titled 'Pending Release of Shares from Voluntary Escrow' by Telix Pharmaceuticals Limited. It discusses the release of shares from escrow related to a prior acquisition, referencing ASX Listing Rule 3.10A. The content is an announcement about share release timing and conditions, not a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. The document length is 5848 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report itself, but rather a regulatory announcement about share escrow release. Therefore, the appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-22 English
Telix Notice of AGM, Proxy Form and Online Guide 33 pages 4.0MB
Regulatory Filings
2024-04-21 English
Pending Release of Shares from Voluntary Escrow 2 pages 148.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release titled 'Pending Release of Shares from Voluntary Escrow' by Telix Pharmaceuticals Limited. It discusses the release of shares from escrow related to a prior acquisition, referencing ASX Listing Rule 3.10A. The content is an announcement about share release timing and does not contain financial statements, detailed financial performance, or management discussion. It is not a report but a regulatory announcement about share capital status. The document length is about 5795 characters, which is relatively short and focused on a specific capital event. This fits best under the category of Share Issue/Capital Change (SHA), as it concerns changes in share capital status (release from escrow).
2024-04-17 English
Telix Q1 2024 Revenue and Business Update 3 pages 174.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Q1 2024 Revenue and Business Update' from Telix Pharmaceuticals Limited. It provides unaudited quarterly revenue figures, operational highlights, recent acquisitions, and full year 2024 guidance. The content includes financial performance data for the quarter ended 31 March 2024, business updates, and forward-looking statements. It is not a full annual report or audit report, nor is it a transcript or presentation. The document is comprehensive and contains substantive financial data and analysis for a quarter, fitting the definition of an Interim / Quarterly Report (IR).
2024-04-16 English
Regulatory Filings 2024
Regulatory Filings
2024-04-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.